Proto Script Pharmaceutical Corp.
PSCR · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 120.3% | -17.3% | 37.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.8% | 26.3% | 77.6% | 0.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -33.9% | -213.5% | -189.3% | -378.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$7 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$1 | -$7 |
| % Margin | -112.6% | -290.8% | -365.8% | -7,238.9% |
| EPS | -0.006 | -0.007 | -0.003 | -0.077 |
| % Growth | 14.7% | -100% | 95.6% | – |
| EPS Diluted | -0.006 | -0.007 | -0.003 | -0.077 |
| Weighted Avg Shares Out | 49 | 49 | 151 | 94 |
| Weighted Avg Shares Out Dil | 49 | 49 | 151 | 94 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -64.9% | -184.8% | -66.7% | -376.7% |